While glucose metabolism alone does not appear to influence plasma PCSK9 concentrations directly, T2DM may modulate the relationship between PCSK9 and atherogenic lipid markers such as non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB) [108]. This evidence concerns the gene APOB and type 2 diabetes mellitus.